B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: clinical experience and future perspectives
Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long-term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable remissions and to improve the quality of life o...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2020
|
| In: |
International journal of cancer
Year: 2020, Volume: 147, Issue: 8, Pages: 2029-2041 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.33002 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.33002 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33002 |
| Author Notes: | Leopold Sellner, Fuli Fan, Nicola Giesen, Maria-Luisa Schubert, Hartmut Goldschmidt, Carsten Müller-Tidow, Peter Dreger, Marc S. Raab, Michael Schmitt |
| Summary: | Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long-term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable remissions and to improve the quality of life of MM patients. |
|---|---|
| Item Description: | First published: 09 April 2020 Gesehen am 05.01.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.33002 |